Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer

doi:10.5246/jcps.2021.03.021

Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer

Journal of Chinese Pharmaceutical Sciences ◽

10.5246/jcps.2021.03.021 ◽

2021 ◽

Vol 30 (3) ◽

pp. 253-263

Keyword(s):

Lung Cancer ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Effectiveness Analysis ◽

Line Therapy ◽

Epidermal Growth

Download Full-text

Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations

Oncotarget ◽

10.18632/oncotarget.24386 ◽

2018 ◽

Vol 9 (36) ◽

pp. 24237-24247 ◽

Cited By ~ 6

Author(s):

Chih-Yen Tu ◽

Chuan-Mu Chen ◽

Wei-Chih Liao ◽

Biing-Ru Wu ◽

Chih-Yu Chen ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Epidermal Growth

Download Full-text

Management of patients with epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) after radiological progression to first-line therapy with gefitinib.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e19124 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e19124-e19124

Author(s):

Yukio Hosomi ◽

Chiharu Tanai ◽

Kiyotaka Yoh ◽

Yasushi Goto ◽

Yasuo Ohashi ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Radiological Progression ◽

First Line Therapy ◽

Line Therapy ◽

Epidermal Growth

Download Full-text

Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations

Annals of Translational Medicine ◽

10.21037/atm.2016.12.64 ◽

2017 ◽

Vol 5 (1) ◽

pp. 11-11

Author(s):

Shinkyo Yoon ◽

Dae Ho Lee ◽

Sang-We Kim

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Epidermal Growth

Download Full-text

9019 POSTER DISCUSSION Safety Analysis of Patient Subgroups Defined by Low and High Tumour Epidermal Growth Factor Receptor (EGFR) Expression in FLEX Study Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Chemotherapy With or Without Cetuximab as First-Line Therapy

European Journal of Cancer ◽

10.1016/s0959-8049(11)72331-0 ◽

2011 ◽

Vol 47 ◽

pp. S598

Author(s):

J. von Pawel ◽

R. Pirker ◽

J.R. Pereira ◽

M. Krzakowski ◽

K. Park ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Egfr Expression ◽

Epidermal Growth ◽

Patient Subgroups

Download Full-text

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

British Journal of Cancer ◽

10.1038/sj.bjc.6603393 ◽

2006 ◽

Vol 95 (8) ◽

pp. 998-1004 ◽

Cited By ~ 216

Author(s):

H Asahina ◽

◽

K Yamazaki ◽

I Kinoshita ◽

N Sukoh ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Epidermal Growth

Download Full-text

PMD19 COST-EFFECTIVENESS OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION TESTING IN THE SELECTION OF FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER IN ONTARIO

Value in Health ◽

10.1016/j.jval.2011.02.459 ◽

2011 ◽

Vol 14 (3) ◽

pp. A82 ◽

Cited By ~ 4

Author(s):

W. Chen ◽

P. Ellis ◽

L. Levin ◽

M. Krahn

Keyword(s):

Lung Cancer ◽

Receptor Gene ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Epidermal Growth ◽

Selection Of

Download Full-text

Pharmacoeconomic Aspects of Different Inhibitors of Tyrosine Kinase in First-Line Therapy of Patients with Advanced Non-Small Cell Lung Cancer with A Mutation in Epidermal Growth Factor Receptor (EGFR) Gene

Value in Health ◽

10.1016/j.jval.2016.09.2139 ◽

2016 ◽

Vol 19 (7) ◽

pp. A720

Author(s):

VV Ryazhenov ◽

SG Gorokhova ◽

V Gorokhov

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Egfr Gene ◽

First Line Therapy ◽

Line Therapy ◽

Epidermal Growth

Download Full-text

Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer

Anti-Cancer Drugs ◽

10.1097/cad.0000000000000268 ◽

2015 ◽

Vol 26 (9) ◽

pp. 995-1003 ◽

Cited By ~ 10

Author(s):

Sávia R.C. Normando ◽

Felipe M. Cruz ◽

Auro del Giglio

Keyword(s):

Receptor Tyrosine Kinase ◽

Kinase Inhibitors ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Epidermal Growth

Download Full-text

Use of Epidermal Growth Factor Receptor Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer to Determine Erlotinib Use as First-Line Therapy

PLoS Currents ◽

10.1371/currents.rrn1245 ◽

2011 ◽

Vol 3 ◽

pp. RRN1245 ◽

Cited By ~ 2

Author(s):

Naoko Ishibe ◽

Josh Carlson ◽

Scott David Ramsey ◽

Andrew Freedman ◽

Sheri Schully

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Epidermal Growth

Download Full-text

9000 ORAL Epidermal Growth Factor Receptor (EGFR) Expression as a Predictive Biomarker of Survival in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving First-Line Therapy With Cetuximab Combined With Chemotherapy in the FLEX Trial

European Journal of Cancer ◽

10.1016/s0959-8049(11)72312-7 ◽

2011 ◽

Vol 47 ◽

pp. S591 ◽

Cited By ~ 1

Author(s):

K. O'Bvrne ◽

L. Paz-Ares ◽

J.R. Pereira ◽

J. von Pawel ◽

R. Ramlau ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Predictive Biomarker ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Egfr Expression ◽

Epidermal Growth

Download Full-text